Influenza B virus B/Massachusetts/2/2012 antigen (MDCK cell derived, propiolactone inactivated)

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Influenza B virus B/Massachusetts/2/2012 antigen (MDCK cell derived, propiolactone inactivated)
Accession Number
DB11000
Type
Biotech
Groups
Approved
Biologic Classification
Vaccines
Other vaccines
Description

A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.

There are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.

Synonyms
Not Available
Active Moieties
NameKindUNIICASInChI Key
Influenza B virus B/Massachusetts/2/2012 hemagglutinin antigen (MDCK cell derived, propiolactone inactivated)hemagglutininMXW705H85LNot AvailableNot applicable
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
FlucelvaxInfluenza B virus B/Massachusetts/2/2012 antigen (MDCK cell derived, propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/Brisbane/10/2010 (H1N1) antigen (MDCK cell derived, propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/Texas/50/2012 X-223A (H3N2) antigen (MDCK cell derived, propiolactone inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularNovartis Vaccines And Diagnostics, Inc.2014-07-012015-06-30Us
FlucelvaxInfluenza B virus B/Massachusetts/2/2012 antigen (MDCK cell derived, propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/Brisbane/10/2010 (H1N1) antigen (MDCK cell derived, propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/Texas/50/2012 X-223A (H3N2) antigen (MDCK cell derived, propiolactone inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularNovartis Vaccines and Diagnostics GmbH2013-08-302014-06-30Us
Medical Provider Single Use EZ Flu Shot Flucelvax 2014-2015 KitInfluenza B virus B/Massachusetts/2/2012 antigen (MDCK cell derived, propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/Brisbane/10/2010 (H1N1) antigen (MDCK cell derived, propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/Texas/50/2012 X-223A (H3N2) antigen (MDCK cell derived, propiolactone inactivated) (15 ug/0.5mL) + Isopropyl alcohol (70 mL/100mL)KitTopicalAsclemed Usa, Inc.2013-07-012015-06-30Us
Categories
Not Available
UNII
4BT5P2A4XF
CAS number
Not Available

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2RecruitingBasic ScienceFlu caused by Influenza1
2RecruitingBasic ScienceHealthy Volunteers1
4Active Not RecruitingPreventionFlu caused by Influenza1
4CompletedOtherAsthma / Influenza Vaccines in Asthma Populations1
4CompletedPreventionImmune Response / Influenza, Human2
4Not Yet RecruitingBasic ScienceFlu caused by Influenza1
4RecruitingBasic ScienceFlu caused by Influenza1
Not AvailableActive Not RecruitingNot AvailableFetal Malformation / Influenza, Human / Pregnancy1
Not AvailableCompletedNot AvailableFlu caused by Influenza / Influenza A H1N1 / Influenza A H3N2 / Influenza A Virus Infection / Influenza Type B / Influenza, Human / Vaccine Reaction1
Not AvailableWithdrawnNot AvailablePregnant Women, Influenza1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Injection, suspensionIntramuscular
KitTopical
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on December 01, 2015 13:05 / Updated on February 06, 2020 13:04